Injection of tocilizumab-bavi, 1 mg, for hospitalized adult COVID-19 patients needing respiratory support

This code represents a single-dose injection of tocilizumab-bavi (Tofidence), an IL-6 receptor antagonist biosimilar to tocilizumab (Actemra), administered intravenously to hospitalized adult patients requiring supplemental oxygen, mechanical ventilation, or ECMO due to COVID-19. It is used as an immunomodulatory agent to mitigate the cytokine release syndrome associated with severe COVID-19 infection. This is a biosimilar product and is not interchangeable with the reference product code without payer-specific guidance.

This code applies when tocilizumab-bavi is administered in the inpatient hospital setting to adults with confirmed COVID-19 who meet oxygen/ventilatory support criteria per FDA authorization or approval. Supporting documentation should include the confirmed COVID-19 diagnosis, the patient's respiratory support status at time of administration, and the specific biosimilar product name and NDC. It should not be used for outpatient or non-COVID-19 indications such as rheumatoid arthritis or cytokine release syndrome from CAR-T therapy.

• Distinguish carefully between tocilizumab-bavi and other tocilizumab biosimilars or the reference biologic; each has a distinct HCPCS code — using the wrong product code is a common audit trigger.
• Verify the unit of service definition for this code; billing units must align with the actual dose administered and the per-unit quantity specified in the code descriptor.
• Medicare and commercial payers may require prior authorization or specific COVID-19 diagnosis coding (e.g., U07.1) as a covered diagnosis on the claim; confirm payer-specific coverage policies before submission.